| Document |
Document Title |
|
WO/2018/044991A1 |
This disclosure relates to thiopicolinamides of Formula I and their use as fungicides.
|
|
WO/2018/041804A1 |
The present invention relates to a process for preparing 3-(2-hydroxybenzoyloxy)-4-(trimethylammonio)butyrobetaine hydrochloride of the formula (I), wherein the process comprises the reaction of 3-hydroxy-4-(trimethylammonio)butyrobetain...
|
|
WO/2018/035610A1 |
The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging: (Formula (I)).
|
|
WO/2018/037115A1 |
The present invention provides an aqueous composition comprising a silicon complex. The composition comprises (i) a monomeric organosilanolate that comprises 1 to 3 oxygen atoms per silicon atom, said organosilanolate being of formula (R...
|
|
WO/2018/033883A2 |
The invention provides for a synthesised ester intermediate of formula 1. Formula 1 Wherein and wherein R may be a saturated or unsaturated fatty acid (C12-C20).
|
|
WO/2018/025892A1 |
The purpose of the present invention is to provide a novel polymerizable triptycene derivative compound, which has a structure in which three benzene rings arranged around barrelene having a triptycene skeleton are capable of balanced ro...
|
|
WO/2018/023116A1 |
Provided herein are isotopically labeled reagents, including isotopically labeled small molecules and peptides, that can be used to detect and/or quantify β-N-methylamino-L-alanine (BMAA) in a sample. The reagents can be used as stable ...
|
|
WO/2018/021010A1 |
Provided is a method for producing glycine with which it is possible to obtain glycine at a higher yield than with conventional methods, when glycine is synthesized from glycinonitrile. The method for producing glycine is characterized i...
|
|
WO/2018/021338A1 |
The present invention is a method for producing a specific α-amino acid in which a specific α-amino acid amide and water are reacted with each other in the presence of a zirconium compound, wherein the zirconium compound contains zirco...
|
|
WO/2018/014140A1 |
Disclosed herein is a method for multimodal imaging during a medical procedure using magnetic resonance imaging (MRI) and Raman optical imaging which involves administering an MRI imaging contrast agent that a chemical structure having c...
|
|
WO/2018/016611A1 |
Provided is a novel therapeutic agent for glaucoma, which has an sGC-activating activity. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an active ingredient, a compound represented by formula (I-a) o...
|
|
WO/2018/015677A1 |
The invention relates to the field of resolution of chiral compounds existing in the form of two optical antipodes (enantiomers), such as Baclofen. More particularly, the invention relates to the production of the pure enantiomer (R)(-) ...
|
|
WO/2018/012459A1 |
An oxygen separation membrane which is configured of a porous material and a complex in the form of a liquid, said complex being internally contained in the porous material, and wherein: the complex contains a metal salen complex or a de...
|
|
WO/2018/004945A1 |
A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO by providing a composition comprising a compound set forth in Formula (I):
|
|
WO/2017/222043A1 |
The purpose of the present invention is to provide: a crystal of HMB amino acid salt, which is easy to handle and is highly soluble; and a production method of said crystal. According to the present invention, a crystal of HMB amino acid...
|
|
WO/2017/222921A1 |
Substituted derivatives of 2-hydroxyisophthalic acid are provided, as well as new synthetic routes for making 2-hydroxyisophthalic acid and the substituted derivatives. Potential uses of the derivatives in a variety of applications are a...
|
|
WO/2017/221079A1 |
The present invention relates to a mycotoxin adsorbant based on a betaine derivative and highly specific for type A and B trichothecenes, especially for vomitoxin (or deoxynivalenol) and T-2 toxin, and to a method for preparing said myco...
|
|
WO/2017/220308A1 |
Process for making a powder or granule containing at least one chelating agent selected from alkali metal salts of methyl glycine diacetic acid (MGDA) and glutamic acid diacetate (GLDA) and iminodisuccinic acid (IDS), said process compri...
|
|
WO/2017/216299A1 |
The object of the present invention are compounds comprising at least one donor group and at least one acceptor group, as described herein, which are characterized by a pronounced CT character. The invention also relates to the use there...
|
|
WO/2017/209117A1 |
The present invention relates to a detergent composition for fibres which includes: component (A), namely C17-24 internal olefin sulfonates; component (B), namely a nonionic surfactant; and component (C), namely a metal ion chelating age...
|
|
WO/2017/208258A1 |
The present invention discloses a novel process for the preparation of gadolinium complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-
triazaundecanedioic acid disodium of formula 1 and novel intermediates thereof.
|
|
WO/2017/205588A1 |
This document relates to an aqueous composition comprising chlorambucil and human serum albumin, wherein the chlorambucil and the human serum albumin in the aqueous composition have a ratio by weight from about 1:10 to about 1:2000, wher...
|
|
WO/2017/199513A1 |
The present invention addresses the problem of providing a liquid crystal composition which does not require an alignment treatment or an alignment film on the substrate, and solves this problem by providing a low molecular polar compoun...
|
|
WO/2017/199514A1 |
The present invention addresses the problem of providing a liquid crystal display element that has a liquid crystal composition which does not require an alignment treatment or an alignment film on the substrate, and solves this problem ...
|
|
WO/2017/199512A1 |
The present invention addresses the problem of providing a liquid crystal composition which does not require an alignment treatment or an alignment film on the substrate, and solves this problem by providing a low molecular polar compoun...
|
|
WO/2017/199227A1 |
The present invention relates to a simple economical process for the preparation of 3,4- dihydroxy-2-methyl benzoic acid C1-4 alkyl ester and novel intermediates for use in the process.
|
|
WO/2017/191453A1 |
A metal-EDTA compound/complex for combatting biofilms and/or treating wounds. The compound/complex comprises EDTA and from two to four metal ions. Of those two to four metal ions, at least two are different metal ions selected from Ag, A...
|
|
WO/2017/189311A1 |
Glycan Composites and methods for rendering glycan composites for the treatment of photosynthetic organisms, including the steps of formulating branched glycan deglycosylates into coordination complex compositions resulting in water-born...
|
|
WO/2017/183539A1 |
[Problem] To provide a compound that can be used on an industrial scale. [Solution] A compound represented by general formula (4) or a base adduct thereof. (In the formula, R3 and R4 independently represent a hydrogen atom or the like.)
|
|
WO/2017/183734A1 |
Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt the...
|
|
WO/2017/181118A1 |
The present invention provides methods for producing cannabinoid prodrugs. Also described are pharmaceutically acceptable compositions of the prodrugs and a system for the large-scale production of the prodrugs.
|
|
WO/2017/176974A1 |
The present disclosure relates to a series of biodegradable amino-ester lipid-like nanoparticles. In some embodiments, the biodegradable amino-ester lipid-like nanoparticles are used in methods for the delivery of nucleic acids.
|
|
WO/2017/173019A1 |
This invention relates to novel compositions comprising the reaction product of at least one acetoacetylated polyol and vanillin. The invention also relates to a method of making the novel compositions of the invention comprising the rea...
|
|
WO/2017/168313A1 |
The present invention provides an improved process for preparation of L-threo-(2S,3R)-3-(3.4- dihydroxyphenyl)serine (I) (Droxidopa) and its salts; comprising (a) reaction of the aldehyde compound (III) (as described herein) with Metal c...
|
|
WO/2017/164363A1 |
The present invention provides a liquid softener composition, which is capable of controlling generation of a sulfur-like odor while continuously realizing the fragrance intended in design and which has excellent storage stability at a l...
|
|
WO/2017/161095A1 |
Provided herein are rigid macrocycles comprising a first redox-active subunit and a second redox-active subunit, wherein the first redox-active unit and the second redox-active unit are different subunits. Also provided herein are method...
|
|
WO/2017/160784A1 |
The present invention provides energy-curable compositions comprising aminoacrylates produced by the Michael addition reaction of any blend of highly alkoxylated monomers with any blend of mono- and/or bireactive amines. Suitable highly ...
|
|
WO/2017/160709A1 |
A compound that is selected from the group consisting of 3-(3,4-dichloroanilino)-3-oxopropanoic acid (hereinafter "DCOPA"); N-methyl-DCOPA; N,2-dimethyl-DCOPA; 2-methyl-DCOPA; isobutyl-DCOPA; N-methyl-isobutyl DCOPA; 3-(3,4-bibromoanilin...
|
|
WO/2017/156164A1 |
The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present inve...
|
|
WO/2017/154738A1 |
The present invention addresses the problem of providing a novel method for producing an optically active amine compound that is useful as an intermediate for a medicine, an agrochemical, an electronic material and the like. A method for...
|
|
WO/2017/145097A2 |
The invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, and pharmaceutical compositions comprising the conjugates. Methods of eliciting immune ...
|
|
WO/2017/137955A1 |
The present invention relates to novel chiral 3-(2-(allyloxy)-5-methylphenyl)-N,N-diisopropyl-3-phenylprop
an-1-amine (5) and racemic 3-(2-(allyloxy)-5-methylphenyl)-N,N-diisopropyl-3-phenylprop
an-1-amine () and its use in improved and ...
|
|
WO/2017/133517A1 |
Disclosed are a phosphamide derivative, a method for manufacturing the same, and uses thereof Particularly disclosed are a compound shown by general formula (I) as well as a pharmaceutically acceptable salt or stereisomer (I) thereof, wh...
|
|
WO/2017/132912A1 |
The present invention provides an alkylamine with a benzoalicyclic substituent and an application thereof. More specifically, the invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a...
|
|
WO/2017/133913A1 |
The present invention relates to a process for the N-alkylation of amines by reacting an amine with an orthocarboxylic acid ester and with hydrogen in the presence of a hydrogenation catalyst.
|
|
WO/2017/133429A1 |
The present invention discloses a terpineol and a preparation method and an application thereof. The terpineol has a structure represented by formulas (I) or (II). In formula (I), R is independently selected from C12 to C16 alkyl, -NR1R2...
|
|
WO/2017/134212A1 |
The present invention relates to a one-pot process for the preparation of trans-4-amino-l-cyclohexanecarboxylic acid derivatives where the trans ratio is more than 75% by reaction of a 4-aminobenzoic acid derivative using an appropriate ...
|
|
WO/2017/131097A1 |
Provided is a pharmaceutical composition for the treatment or prevention of a cognitive disease or disorder, the composition comprising a compound represented by formula (1), an enantiomer thereof or diasteriomer thereof, or a pharmaceut...
|
|
WO/2017/131149A1 |
A compound shown by general formula (I-1) (in the formula, all symbols are as stated in the specification.) has selective S1P5 receptor-binding activity. Adjusting this activity makes it possible to obtain a therapeutic agent for S1P5-me...
|
|
WO/2017/131237A1 |
Provided are: a novel artificial single guide RNA (sgRNA) that has an activity equal to or higher than the activity of a natural type sgRNA and shows an improved in vivo stability; and an efficient CRISPR/Cas9 system comprising a combina...
|
